临床药师参与1例迟发性运动障碍病例的治疗
|
摘要
目的探讨临床药师参与临床药物治疗的方式,以及在临床治疗中所发挥的作用。方法临床药师参与1例迟发性运动障碍病例的治疗过程,实施全程药学监护,评估疗效及不良反应。查阅文献资料,与医师探讨拟定治疗方案。结果医师采纳意见后取得了满意的治疗效果。结论临床药师深入临床提供药学服务,可避免延误患者的有效药物治疗,切实提高药物治疗水平和医疗质量。
引文
[1] SAIFEE T A, EDWARDS M J. Tardive movement disorders:_a practical approach[J].Pract Neurol,2011,11(6):341.
[2] 王维治.神经病学:第2版[M].北京:人民卫生出版社,2013:1425.
[3] BHIDAYASIRI R, FAHN S, WEINER W J, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology[J]. Neurology,2013,81(5):463.
[4] 李喆,孙学礼,周澈.迟发性运动障碍病因学研究与治疗进展[J].中国神经精神疾病杂志,2007,33(7):447.
[5] DESMARAIS J E, BEAUCLAIR L, MARGOLESE H C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? [J]. J Psychopharmacol, 2012,26(9):1167.
[6] REVUELTA G J, CLOUD L, AIA P G, et al. Tardive dyskinesias//Albanese AJ,editor.Hyperkinetic movement disorders:differential diagnosis and treatment[M].Chichester:Wiley-Blackwell,2012:331.
[7] 李秋英,王惠玲,段金莲.安坦所致迟发性运动障碍1例[J].中国民康医学,2008,20(23):2769.
[8] 王宁,谭云龙,杨甫德,等. 精神分裂症伴发迟发性运动障碍的血清S100B 蛋白浓度研究[J].中国神经精神疾病杂志,2011,37(9):550.
[9] 王坚. 中枢神经系统运动障碍的诊断和处理[J].神经病学与神经康复学杂志, 2010,15(3):187.
[10] ASSOCIATION A P. Diagnostic and statistical manual of mental disorders: Fifth Edition[M]. Arlington, VA: American Psychiatric Association,2013.
[11] MILLER D D, MCEVOY J P, DAVIS S M, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trials[J]. Schizophr Res,2005,80(1):33.
[12] 赵芳霞,耿卫国.黛力新引起急性肌张力障碍1例[J].临床精神医学杂志,2013,23(3):183.
[13] ALABED S, LATIFEH Y, MOHAMMAD H A, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia[J]. Cochrane Database Syst Rev,2011,13(4):CD000203.
[14] BIALER M. Chemical properties of antiepileptic drugs (AEDs) [J].Adv Drug Deliv Rev,2012,64(10):887.
[15] 胡垒,王立广.丙戊酸钠及氯硝西泮治疗迟发性运动障碍的疗效观察[J].中国医院用药评价与分析,2016,16(2):159.
[16] 朱齐兵,陈慧君,唐小万,等.对1例PICC置管术后感染合并血栓性静脉炎患者的药物监护[J].中国临床药学杂志,2016,25(4):254.
[2] 王维治.神经病学:第2版[M].北京:人民卫生出版社,2013:1425.
[3] BHIDAYASIRI R, FAHN S, WEINER W J, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology[J]. Neurology,2013,81(5):463.
[4] 李喆,孙学礼,周澈.迟发性运动障碍病因学研究与治疗进展[J].中国神经精神疾病杂志,2007,33(7):447.
[5] DESMARAIS J E, BEAUCLAIR L, MARGOLESE H C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? [J]. J Psychopharmacol, 2012,26(9):1167.
[6] REVUELTA G J, CLOUD L, AIA P G, et al. Tardive dyskinesias//Albanese AJ,editor.Hyperkinetic movement disorders:differential diagnosis and treatment[M].Chichester:Wiley-Blackwell,2012:331.
[7] 李秋英,王惠玲,段金莲.安坦所致迟发性运动障碍1例[J].中国民康医学,2008,20(23):2769.
[8] 王宁,谭云龙,杨甫德,等. 精神分裂症伴发迟发性运动障碍的血清S100B 蛋白浓度研究[J].中国神经精神疾病杂志,2011,37(9):550.
[9] 王坚. 中枢神经系统运动障碍的诊断和处理[J].神经病学与神经康复学杂志, 2010,15(3):187.
[10] ASSOCIATION A P. Diagnostic and statistical manual of mental disorders: Fifth Edition[M]. Arlington, VA: American Psychiatric Association,2013.
[11] MILLER D D, MCEVOY J P, DAVIS S M, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trials[J]. Schizophr Res,2005,80(1):33.
[12] 赵芳霞,耿卫国.黛力新引起急性肌张力障碍1例[J].临床精神医学杂志,2013,23(3):183.
[13] ALABED S, LATIFEH Y, MOHAMMAD H A, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia[J]. Cochrane Database Syst Rev,2011,13(4):CD000203.
[14] BIALER M. Chemical properties of antiepileptic drugs (AEDs) [J].Adv Drug Deliv Rev,2012,64(10):887.
[15] 胡垒,王立广.丙戊酸钠及氯硝西泮治疗迟发性运动障碍的疗效观察[J].中国医院用药评价与分析,2016,16(2):159.
[16] 朱齐兵,陈慧君,唐小万,等.对1例PICC置管术后感染合并血栓性静脉炎患者的药物监护[J].中国临床药学杂志,2016,25(4):254.